trending Market Intelligence /marketintelligence/en/news-insights/trending/6qnggcsp5v_laemnnvp95q2 content esgSubNav
In This List

Italy's Menarini Group seeks EMA approval for bacterial infection treatment

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Italy's Menarini Group seeks EMA approval for bacterial infection treatment

The Menarini Group sought European Medicines Agency approval for delafloxacin to treat adults with acute bacterial skin and skin structure infections.

In 2017, Italian drugmaker Menarini obtained the exclusive rights to commercialize the treatment from New Haven, Conn.-based biopharmaceutical company Melinta Therapeutics Inc.

Menarini plans to commercialize the medicine, known as Baxdela in the U.S., as Quofenix in Europe.

The application is based on results of two phase 3 studies, which met both primary goals specified by the EMA and the U.S. Food and Drug Administration.